NAD for addiction isn't an established treatment for alcohol or other drug problems. That includes opioids, such as heroin and certain prescription pain medicines. No randomized human trial has demonstrated that NAD+ safely manages withdrawal or prevents a return to use. A randomized trial assigns people to comparison groups by chance.
NAD+ means nicotinamide adenine dinucleotide, a helper molecule cells use for energy and repair. That biology explains the interest. It doesn't establish that giving extra NAD+ treats addiction. An NAD+ IV drip delivers medication into a vein. It cannot replace addiction care.
NAD for addiction: what the human studies show
The claim has a long history. Paul O'Hollaren's 1961 preliminary report described treating addiction with diphosphopyridine nucleotide, or DPN, an older name for NAD+. It offered uncontrolled case accounts, meaning there was no comparison group to separate treatment effects from other changes. The broader history of NAD+ explains how the molecule entered medical research.
Controlled human research is old and small, and it points the other way. In a 12-day double-blind study published in 1971, people in alcohol withdrawal received 3 g of NAD by mouth daily or a placebo, and the researchers found no significant differences between the groups in laboratory, clinical, behavioral, psychological or sleep measures. That study gave NAD by mouth, not by IV drip.
Braidy and colleagues' 2020 review, Sobriety and Satiety: Is NAD+ the Answer?, explored the biology behind the idea. It also acknowledged limited clinical studies and called for more follow-up.
A 2024 report by Blum and colleagues in Journal of Addiction Psychiatry described 50 people in addiction programs. They received drips combining NAD+ with vitamins and amino acids, the building blocks of proteins. Participants reported lower craving, anxiety and depression scores. Sleep changes weren't statistically significant, meaning the analysis didn't clearly distinguish them from chance variation.
There was no comparison group, and participants were receiving other addiction care. Those results cannot isolate NAD+'s contribution or show that it prevents relapse, a return to substance use.
As of October 29, 2026, the day this article was written, a review published September 10 in Frontiers in Aging is the newest broad look at IV NAD+. It doesn't look at addiction at all. For IV NAD+ in general, it finds small studies, few placebo controls and short follow-up, and calls the evidence insufficient to support routine clinical or wellness use.
NAD+ for alcohol withdrawal: safety comes first
Withdrawal means symptoms that follow reducing or stopping a substance the body has become used to. Managing it safely is a different task from supporting recovery over time.
The National Institute on Alcohol Abuse and Alcoholism's treatment guide explains that alcohol withdrawal can be life-threatening. Symptoms can include seizures. Severe confusion during alcohol withdrawal can signal delirium tremens, a medical emergency described by MedlinePlus.
Sedatives raise a similar concern. Benzodiazepines are medicines used for conditions including anxiety and sleeplessness. FDA's September 23, 2020 safety communication describes potentially life-threatening seizures after abrupt stopping or rapid dose reduction.
An NAD+ infusion hasn't been shown to prevent these emergencies. Clinicians assess withdrawal risk and decide what monitoring and medical treatment are needed. A wellness appointment is not a substitute for that assessment.
What established addiction treatment includes
NAD+ is different from the medicines FDA has reviewed for addiction. NIAAA and the Substance Abuse and Mental Health Services Administration's treatment guide describe these established options:
| Condition | Medicines used in treatment |
|---|---|
| Alcohol use disorder, difficulty controlling drinking despite harm | Naltrexone, acamprosate and disulfiram |
| Opioid use disorder, difficulty controlling opioid use despite harm | Buprenorphine, methadone and naltrexone |
A clinician chooses among them based on current substance use, medical history and treatment goals. Counseling and ongoing support can be part of the plan. The medicines aren't interchangeable, and treatment for ongoing addiction isn't the same as emergency withdrawal care.
GLP-1 medicines, which mimic a hormone involved in appetite, are being studied separately. The semaglutide alcohol-use-disorder trial addresses that research. Findings about one molecule cannot establish a benefit from NAD+.
NAD IV therapy for addiction adds infusion risks
An infusion has preparation and delivery risks even when the hoped-for benefit remains uncertain. In its notice dated October 30, 2024, FDA described food-grade NAD+ used to prepare IV products. It said such ingredients were unsuitable for sterile drugs, meaning germ-free preparations, “without appropriate processing.”
FDA received reports of “severe chills, shaking, vomiting and fatigue,” sometimes requiring medical treatment. It described the reactions as consistent with excessive endotoxins, bacterial material that can cause illness. That wording doesn't prove the cause of every reaction.
As of October 29, 2026, the day this article was written, the Bronx District Attorney's October 7 release says a 27-year-old woman died after an NAD+ IV given by a man not licensed to practice medicine in New York, and that the medical examiner found air entering the IV catheter caused her death. The NAD+ IV death report covers the case; the charges remain allegations.
The NAD+ side-effects guide covers reported reactions. Neither NAD+'s natural presence in cells nor its use in a clinic establishes safety for a particular preparation.
What a provider needs to know before considering NAD+
The review starts with current alcohol and drug use, the last use, previous withdrawal symptoms and any history of seizures. Current addiction treatment, other medicines, pregnancy, heart problems and liver or kidney disease also belong in the conversation.
The provider also needs to know what the person hopes NAD+ will do. NAD+ hasn't been shown to manage withdrawal or reduce craving, and it isn't a substitute for addiction treatment or withdrawal care. The NAD+ decision guide and NAD+ myths guide cover the broader claims.
NAD+ prescribed through Promise is dispensed as a compounded medication, meaning a pharmacy prepares it for a prescription. No NAD+ product has FDA approval, and the compounded formulation is not FDA-approved. FDA explains that it does not verify compounded drugs' safety, effectiveness or quality before marketing. The NAD+ regulatory review covers that record.
A licensed provider may still prescribe — that decision is between you and your doctor. A prescribed route identifies the reviewing clinician and licensed U.S. compounding pharmacy. It doesn't turn limited addiction evidence into an established treatment.
Where addiction treatment starts
SAMHSA's National Helpline provides free, confidential treatment referrals and information. FindTreatment.gov lists treatment services. The helpline connects people with help; it does not provide counseling or emergency withdrawal care.
A useful treatment discussion covers withdrawal safety, available medicines, ongoing support and follow-up. NAD+ remains a separate prescribing question, rather than a replacement for those services.
At Promise, a licensed provider reviews every NAD+ request, and not everyone qualifies.
